Warfarin Dosing in Hispanic and Latino Patients
This observational study is looking at how genetics affect the right dose of warfarin, a blood thinner used to prevent and treat blood clots. Warfarin doses need to be carefully managed to avoid bleeding or new clots. Researchers want to understand why some Hispanic and Latino patients need different warfarin doses by studying their genes. The study aims to identify factors that predict a stable warfarin dose. To join, you must be at least 18 years old, identify as Hispanic or Latino, and already be on a stable warfarin dose. The study is planning to enroll 400 participants, but its current status is unclear.
- Study design
- This is an observational study with no specified phase, planning to enroll 400 participants. It is not a randomized or blinded study.
- What's involved
- You would provide a mouthwash sample or a blood sample (if you are already having blood drawn for a regular appointment).
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint, stable warfarin dose, is measured at the time of enrollment. No further follow-up is specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Pharmacogenomics of Warfarin in Hispanics and Latinos
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Stable warfarin doseAt time of enrollment
Dose of warfarin required to maintain stable INR for at least 2 consecutive clinic visits.